8,679 Matching Annotations
  1. Feb 2024
  2. Apr 2023
    1. those who got the updated booster had one-tenth the risk of being hospitalized compared with those who are unvaccinated

      Basically 65-79 higher seniors are in high risk of being sent to the hospital rather than other people who aren't even vaccines The booster is much more stronger to seniors.

  3. Feb 2023
  4. Jan 2023
    1. Selain itu, isolat virus RaTG13 memiliki nilai kekerabatan 96,1%. Virus ini ditemukan di Yunnan, Cina. Sedangkan isolat virus yang berasal dari tenggiling mempunyai nilai kekerabatan sekitar 91%. Adanya nilai kekerabatan yang tinggi ini dimungkinkan akibat dari evolusi yang telah terjadi dari nenek moyang yang sama.

      Untuk diperhatikan, artikel yang dikutip dengan judul "Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak" sudah di erratum 3 tahun yang lalu (https://pubmed.ncbi.nlm.nih.gov/32315626/)

      Sehingga masuk dalam jangkauan diskusi PubPeer dengan komentar sebagai berikut:

      Readers should become aware of a preprint (DOI: 10.1101/2020.05.07.077016) entitled "The SARS-CoV-2-like virus found in captive pangolins from Guangdong should be better sequenced" that provides critics to the quality of the sequence runs used in Liu et al. 2019 and also in this paper, to infer the genome sequence of Pangolin-CoV.

      This preprint states, in particular, that "I found the genome assemblies of GD/P virus of poor quality, having high levels of missing data. Additionally, unexpected reads in the Illumina sequencing data were identified. The GD/P2S dataset contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus".

      Penting bagi penulis untuk menambahkan informasi kebaharuan dan status riset dan temuan terbaru dari artikel yang dikutip. Semoga menjadi koreksi.

      Salam.

    1. I asked why she thought that was happening, and she said, “Covid”. The lack of socialization, especially at such a key time in life, had made this incoming class the first one that lacked basic manners and social skills.

      Covid has heavily impacted our social/communication skills

  5. Nov 2022
    1. We’re dedicated to providing the highest standards of safety to protect you and your family during your visit to Founders Family Medicine. We screen all patients for COVID-19 symptoms. We also require masks and social distancing at our clinic.

      We’re dedicated to providing the highest standards of safety to protect you and your family during your visit to Founders Family Medicine. We screen all patients for COVID-19 symptoms. We also require masks and social distancing at our clinic.

  6. Sep 2022
    1. The North American Division has put together a series of links to offer guidance about vaccines from national and international health organizations, the General Conference, and healthcare experts — with the COVID-19 vaccine highlighted in particular.
  7. Aug 2022
    1. The socioeconomic disruption associated with COVID-19 represents a highly unusual alteration of the human interaction with the Earth System. This alteration is likely to generate a series of responses, illuminating the processes connecting energy, emissions, air quality and climate, as well as globalization, food security, poverty and biodiversity

      La perturbación socioeconómica asociada a COVID-19 representa una alteración muy inusual de la interacción humana con el Sistema Tierra. Es probable que esta alteración genere una serie de respuestas que iluminen los procesos que conectan la energía, las emisiones, la calidad del aire y el clima, así como la globalización, la seguridad alimentaria, la pobreza y la biodiversidad.

    1. Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

    1. Gilbert, P. B., Montefiori, D. C., McDermott, A., Fong, Y., Benkeser, D. C., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B. C., O’Connell, S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., … Teams, U. S. G. (USG)/CoVPN B. (2021). Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. MedRxiv, 2021.08.09.21261290. https://doi.org/10.1101/2021.08.09.21261290

    1. Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., … Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, S0140673621027173. https://doi.org/10.1016/S0140-6736(21)02717-3 s

    1. Chadeau-Hyam, M., Wang, H., Eales, O., Haw, D., Bodinier, B., Whitaker, M., Walters, C. E., Ainslie, K. E. C., Atchison, C., Fronterre, C., Diggle, P. J., Page, A. J., Trotter, A. J., Ashby, D., Barclay, W., Taylor, G., Cooke, G., Ward, H., Darzi, A., … Elliott, P. (2022). SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): A series of cross-sectional random community surveys. The Lancet Respiratory Medicine, 0(0). https://doi.org/10.1016/S2213-2600(21)00542-7

    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. Sadoff, J., Gars, M. L., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., Groot, A. M. de, Scheper, G., Hendriks, J., Ruiz-Guinazu, J., Struyf, F., Hoof, J. V., Douoguih, M., & Schuitemaker, H. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (p. 2021.08.25.21262569). https://doi.org/10.1101/2021.08.25.21262569

    1. Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., … Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 1–9. https://doi.org/10.1038/s41586-021-04120-y

    1. Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R., Kyasani, M., Manoharan, S. K., Medigeshi, G., Singh, J., Shaman, H., Singh, C., & Rao, A. V. (2022). Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies (p. 2022.03.08.22271822). medRxiv. https://doi.org/10.1101/2022.03.08.22271822

    1. Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … Self, W. H. (2022). Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ, 376, e069761. https://doi.org/10.1136/bmj-2021-069761

    1. Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Studley, R., Crook, D., Peto, T. E. A., Walker, A. S., & Pouwels, K. B. (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01410-w

    1. Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

    1. Sandra Ciesek. (2021, December 8). Unsere ersten Daten zur Neutralisation von Omicron versus Delta sind fertig: 2x Biontech, 2x Moderna, 1xAZ/1x Biontech nach 6 Monaten 0% Neutralisation bei Omicron, auch 3x Biontech 3 Monate nach Booster nur 25% NT versus 95% bei Delta. Bis zu 37fache Reduktion Delta vs. Omicron https://t.co/w0gHww26sg [Tweet]. @CiesekSandra. https://twitter.com/CiesekSandra/status/1468465347519041539

    1. Collier, A. Y., Brown, C. M., Mcmahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D., Ansel, J. L., Rowe, M., Sellers, D., Ahmad, K., Aguayo, R., Anioke, T., Gardner, S., Siamatu, M., Rivera, L. B., Hacker, M. R., Madoff, L. C., & Barouch, D. H. (2021). Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts (p. 2021.10.18.21265113). https://doi.org/10.1101/2021.10.18.21265113

    1. John Bye [@_johnbye]. (2021, October 6). The new covid sceptic All Party Parliamentary Group on Pandemic Response and Recovery is backed by Gupta and Heneghan’s Collateral Global to the tune of over £30,000. £5,000 in financial benefits plus £25,501—£27,000 benefits in kind (CG is acting as their secretariat). Https://t.co/qll20Sg9aA [Tweet]. Twitter. https://twitter.com/_johnbye/status/1445867760819396608

    1. Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x

    1. Dr Dan Goyal. (2022, March 15). What’s been happening This Week in Covid? The schism between reality and policy grew even wider this week... Omicron B.2 sent cases soaring and stock markets sinking! #TheWeekInCovid [Tweet]. @danielgoyal. https://twitter.com/danielgoyal/status/1503699425427968001